Citations

Clear

16280 citation(s) found for "Yu, David".

Clinical and Diagnostic Complexity in ELISA- and SRA-Negative Monoclonal Gammopathy of Thrombotic Significance
Kanack, Adam J. , Mauch, Emily, Splinter, Noah P., Kohlhagen, Mindy , Murray, David , Jones, Curtis G., Johns, Gretchen S., Pabmanabhan, Anand, Leung, Nelson

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 5522-5522

10.1182/blood-2024-210772 Get It

Monoclonal gammopathy of thrombotic significance (MGTS) is a recently recognized thrombophilia characterized by the production of a monoclonal antibody that binds to platelet factor 4 (PF4) and stimulates platelet activation (Blood. 2022 Jul 7;140(1):73-77). Typical signs of MGTS include a history of recurrent thrombosis, persistent thrombocytopenia, and positive laboratory results in PF4/polyanion enzyme-linked immunosorbent assay (ELISA) and serotonin release assay (SRA) testing, as in the related thrombotic disorder heparin-induced thrombocytopenia (HIT). Here, we present a case of MGTS, presenting with transient thrombocytopenia coincident with thrombotic episodes and negative test results in SRA and PF4/polyanion-based testing platforms (ELISAs and automated assays). A 56-year-old male patient initially presented with acute left lower extremity deep vein thrombosis (DVT) and a pulmonary embolism. Following the administration of warfarin, the patient experienced a second DVT four months later and was transitioned to a factor Xa inhibitor. Fifty-two months later, the patient developed occlusion of the splenic and superior mesenteric veins despite additional anticoagulation therapy. Further testing led to a diagnosis of an IgG2 kappa monoclonal gammopathy of undetermined significance (MGUS). Eleven months later, the patient again suffered breakthrough thrombosis, specifically radial artery thrombosis, and a thrombotic cerebrovascular accident, leading to the addition of aspirin to the patient's treatment regimen. Notably, where detailed blood counts were available in the patient's clinical history, the patient experienced only transient thrombocytopenia coinciding with his two most recent thrombotic episodes and has had platelet counts in the normal range in the four-year period since his last thrombotic event. After initiating dual anticoagulant/antiplatelet therapy, the patient has not developed recurrent thrombocytopenia or new thrombotic events. Antigen-based and functional testing for HIT antibodies (ELISA, SRA, and automated immunoassays) were negative in this patient, unlike in the previously described index case of MGTS, where serological testing mimicked classical HIT serology (i.e., HIT ELISA and SRA positivity). The sample was also non-reactive in a vaccine-induced immune thrombotic thrombocytopenia (VITT)-specific ELISA employing uncomplexed PF4 targets, as previously described (Am J Hematol. 2022 May;97(5):519-526). Conversely, the patient's antibody consistently stimulated platelet activation in a PF4- and IgG-dependent manner in functional testing using PF4-treated platelets. This included PF4-treated platelets that were freshly isolated and used in the PF4-dependent P-selectin expression assay (PEA) and cryopreserved platelets used in the thrombospondin-1 release assay. Interestingly, consistently positive PEA results have been documented from four samples over the last four years, during which the patient had normal platelet counts. To further characterize the patient's IgG2 MGUS antibody, the patient's monoclonal was immuno-enriched. Patient sera and the immuno-enriched MGUS were then compared by mass spectrometry, which generated identical mass profiles. After confirming the effective enrichment of the patient's MGUS by mass spectrometry, the antibody was de novo sequenced or “reverse-engineered” to obtain the antibody's amino acid sequence. The antibody was then expressed and tested in ELISA-based and functional platelet assays. Importantly, the recombinant antibody replicated the PF4-dependent platelet activation observed with patient serum and did not bind PF4/polyanion targets in ELISA testing. Together, these data strongly support the identification of a new class of ELISA- and SRA-negative anti-PF4 monoclonal antibodies that cause MGTS. This case illustrates the diagnostic challenges in MGTS. MGTS patients may not exhibit persistent thrombocytopenia, and diagnostic tests for detecting HIT antibodies may be ineffective in accurately diagnosing this new thrombophilia. This case emphasizes the importance of reviewing platelet counts in the peri-thrombotic period to recognize transient thrombocytopenia and establishes the utility of PF4-enhanced functional assays to detect pathogenic anti-PF4 antibodies, even in settings where classical HIT testing (i.e., ELISA/SRA) is negative.
Early Insights into Real-World Iptacopan Use Among Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States: The Apprise-PNH Data Platform
Yen, Glorian , Kuypers, Nicholas, Paulose, Jincy, Chanpura, Mohin , Lee, Soyon , Barone, Joseph G., Stutts, Jacob, Buchan, Tayler A. , Buchan, Claire, Kim, Inkyu , Waheed, Anem , Dingli, David , Stutts, Jacob, Tang, Jackson

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 5668-5668

10.1182/blood-2024-194425 Get It

Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening hematological disorder affecting approximately 24 people per million in the United States (US). Iptacopan, the first orally administered monotherapy for PNH, received US Food and Drug Administration approval in December 2023. APPRISE-PNH (A Patient Platform for Real-world data on Iptacopan in the United StatEs for patients with PNH) is a data platform designed to capture comprehensive real-world information on patients with PNH treated with iptacopan in the US. This interim analysis aims to provide early insights into the characteristics and treatment patterns of patients enrolled in APPRISE-PNH to date. Methods: APPRISE-PNH is a retrospective, longitudinal, data platform including adult patients (age ≥18 years) with PNH treated with iptacopan in the US real-world setting. Consenting patients in the US are recruited through the iptacopan distribution network. The present analysis includes data from patients enrolled between July 2 and July 26, 2024, with additional data collection expected through the remainder of 2024 and 2025. Patient characteristics and treatment patterns were evaluated descriptively. Duration of therapy was measured from the date of iptacopan initiation until the date of iptacopan discontinuation or data cut-off, whichever occurred first. Treatment adherence was measured using both the medication possession ratio (MPR), calculated as the ratio of the total days supply to days covered, and the proportion of days covered (PDC), calculated as the ratio of days with supply to days covered. Results: As of July 26th, 2024, nine patients with PNH have enrolled in the APPRISE-PNH data platform. The median age at the start of iptacopan therapy was 44 years (interquartile range [IQR] 40-73 years), seven (78%) patients were female, and four (44%) were covered by commercial insurance. Overall, two (22%) patients were treatment-naïve at the start of iptacopan therapy, while seven (78%) patients had received prior complement-inhibitor (CI) therapy for PNH (44% ravulizumab, 44% eculizumab, 33% pegcetacoplan). The median duration of iptacopan therapy was 2.0 months (IQR 1.5-2.9 months). All patients received iptacopan 200 mg twice daily (as per the product label) and the median number of fills was 2.0 (IQR 1.0-3.0). At the time of data cut-off, no patients had discontinued iptacopan therapy. The MPR in this group of patients was 136% (IQR 114%-150%) and PDC was 100% (IQR 100%-100%). Conclusions: These are the first data from the APPRISE-PNH data platform and represent the first insights into real-world use of iptacopan in the US. Many patients enrolled in APPRISE-PNH had previously received CI therapy for PNH. Treatment adherence, as indicated by both the MPR and PDC, was high across iptacopan-treated patients. Enrollment into the APPRISE-PNH data platform is currently ongoing; data from additional patients, additional laboratory and clinical outcomes, and longer follow-up data are expected to be available at the time of presentation.
Light Chain Multiple Myeloma - Clinical Characteristics and Outcomes
Zanwar, Saurabh , Abdallah, Nadine , Hayman, Suzanne R. , Kapoor, Prashant , Kourelis, Taxiarchis , Warsame, Rahma , Hwa, Yi L. , Hobbs, Miriam, Fonder, Amie , Kumar, Shaji , Bolarinwa, Abiola , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Muchtar, Eli , Gonsalves, Wilson I. , Dingli, David , Leung, Nelson , Cook, Joselle , Binder, Moritz , Lin, Yi , Rogers, Michelle G., Jevremović, Dragan , Rajkumar, S. Vincent

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 6950-6950

10.1182/blood-2024-208468 Get It

Introduction: Light chain multiple myeloma (LCMM) is a distinct subtype of multiple myeloma (MM) characterized by the exclusive production of immunoglobulin light chains, unlike the common form of MM that produces the complete immunoglobulin. There is a paucity of literature on the specific tumor cell alterations leading to light chain-only disease as opposed to the typical presentation in MM. Additionally, data on treatment response and outcomes in this subgroup of patients is sparse. This study explores the differences in baseline characteristics, including cytogenetic abnormalities and treatment response between LCMM and multiple myeloma with heavy chain involvement. Materials and Methods: We reviewed patient charts to obtain clinical and laboratory information for individuals diagnosed with LCMM and those with heavy chain MM (comparison cohort) from 2004 to 2022. Patients were matched for age, sex, and year of diagnosis. Data collected included treatment assessment, overall survival, and progression-free survival (PFS). Associations between outcomes and categorical variables were analyzed using the chi-square test, while the Mann-Whitney U test was employed to compare medians. Progression-free survival following initiation of initial therapy and overall survival were assessed using Kaplan-Meier analysis. The Mayo Clinic Institutional Review Board (IRB) approved the study. Results: We identified 848 patients, representing 17.1% of newly diagnosed MM cases. The median age of the LCMM cohort was 63 years (range 16-92), with a female-to-male ratio of 1:5. The LCMM cohort had higher levels of lactate dehydrogenase (LDH), beta-2 microglobulin (p<0.0001), higher baseline creatinine (p<0.0001) and calcium (p<0.0001). The two cohorts had no significant difference in the International Staging System (ISS) or revised ISS (R2-ISS). Additionally, hemoglobin (Hb) and white blood cell count at presentation were higher in the LCMM cohort. Chromosome 1 abnormalities were lower in the LCMM cohort: 1q gain (OR-0.7; 95% CI: 0.6-0.9) and 1p deletion (OR-0.7; 95% CI: 0.6-0.9, p=0.02). Likewise, the frequencies of trisomies and hyperdiploidy were lower in the LCMM cohort, with odds ratios of 0.32 (p=0.012) and 0.37 (p<0.001), respectively. The frequencies of translocations t(4;14) (OR-0.35, p<0.001) and t(14;16) (OR-0.6, p=0.03) were lower in LCMM compared to heavy chain MM. In contrast, the frequencies of t(11;14) (OR-3.4) and t(6;14) (OR-4.9) and deletion of 13q(OR-1.3) was higher in the LCMM cohort. There was no significant difference in the occurrence of del(17p)/TP53 abnormalities. The median PFS after the first regimen was shorter in the LCMM cohort (23 months vs. 27 months, p=0.03), and this difference remained significant after adjusting for baseline adverse prognostic indices and treatment regimen. Median PFS in LCMM patients with monoclonal antibody (Mab) as part of their treatment was 37 months vs. 23 months (Proteasome Inhibitor or immunomodulator-based regimen without Mab), though this difference is not statistically significant p=0.87. No significant difference was found in overall survival between the two groups. Conclusion: This study highlights unique features of light chain multiple myeloma, including increased frequencies of specific cytogenetic abnormalities. Further evaluation of observed differences in cytogenetic abnormalities may enhance our understanding of LCMM and potentially guide baseline treatment choices to improve outcome.
Current Trends of Severe Renal Impairment in Newly Diagnosed Multiple Myeloma: A Single-Center Experience in a Low Socio-Economic Population
Hammami, M Bakri , Shivakumar, J, Samuel, Nina, Gor, Rajvi , Kornblum, Noah , Shastri, Aditi , Gupta, Ridhi , Konopleva, Marina , Feldman, Eric J. , Verma, Amit , Cooper, Dennis , Bakri, Hammami M , Shivakumar, Jeevan, Goldfinger, Mendel , Shapiro, Lauren, Levitz, David , Gritsman, Kira , Sica, Roberto Alejandro , Mantzaris, Ioannis , Shah, Nishi

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 6999-6999

10.1182/blood-2024-208770 Get It

Background: Recent advancements in multiple myeloma (MM) diagnosis and treatment significantly improved patients' survival and quality of life. Severe Renal Impairment (RI) remains a significant challenge in newly diagnosed MM (NDMM), complicating treatment and affecting outcomes. Prior studies reported improved overall renal recovery in the era of novel therapies. However, there is a lack of evidence documenting the outcomes of patients presenting with severe RI. We present an updated analysis of the characteristics and outcomes of patients with NDMM presenting with severe RI in an ethnically diverse, low socio-economic population. Methods: A single-center retrospective review of patients with NDMM presenting to Montefiore Medical Center (Bronx, New York) was conducted from 2011-2023. Severe RI was defined as an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m². MM risk was assessed using the mSMART 3.0 tool. Results: Out of 284 patients with NDMM, 58 (20%) patients presented with severe RI. Black patients (p = 0.018) and older adults (64 years vs 60 years, p value 0.032) were more likely to present with severe RI. Severe RI at diagnosis correlated with high-risk myeloma (p = 0.002), high R-ISS stage (p < 0.001), and a lower likelihood of receiving stem cell transplants (p < 0.001). Among those with severe RI, 23/58 required dialysis of which 6/23 were taken off dialysis at last follow-up after renal recovery. Median eGFR at diagnosis, 6 months and 1 year after diagnosis was 11, 23 and 23.5 ml/min/1.73 m2, respectively. 14 out of 58 patients (39%) achieved renal recovery to eGFR > 30 one year post-diagnosis, with no significant difference in race, sex, or ethnicity. The most common first-line treatment for patients with severe RI was CyBorD (62%). The median time from diagnosis to first treatment (including plasma exchange) was 10 days. By the last follow-up, 35/58 patients (60%) had a stem cell transplant, with a median time from diagnosis to transplant of 275 days. The median overall survival (OS) for patients with severe RI at diagnosis was 49 months, while it was not reached for those without severe RI (p < 0.001). Early death (≤ 2 months after diagnosis) occurred in 2 patients, both with severe RI. Among patients with severe RI, multivariate Cox regression survival analysis showed that achieving free light chain (FLC) below 500 mg/L (HR 0.212, p < 0.001) and receiving a stem cell transplant (HR 0.209, p 0.002) improved outcome. Conclusions: Despite improvements in the life expectancy of patients with MM, severe renal failure remains a challenge, particularly among minorities. Socioeconomic factors need to be explored as a contributor to outcomes in patients with severe RI. Achieving FLC clearance and undergoing stem cell transplant may play a role in survival in patients with NDMM and severe RI.
Real-World Adherence with Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria Compared with Previously Reported Oral Medication Adherence Rates
Mulherin, Brian , Czech, Barbara, Panse, Jens , Dingli, David , Hillmen, Peter

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 5680-5680

10.1182/blood-2024-203541 Get It

Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and severe hematologic disorder caused by somatic mutation(s) in hematopoietic stem cells, which results in dysregulation of complement activation and complement-mediated hemolysis. Several complement inhibitors are approved for PNH, including the intravenous or subcutaneous C5 inhibitors (C5is) eculizumab, ravulizumab, and crovalimab; the subcutaneous self-administered C3 inhibitor pegcetacoplan; and the oral factor B inhibitor iptacopan and factor D inhibitor danicopan (as add-on therapy to a C5i). Although oral self-administered medications would be expected to lighten treatment burden over injectable medications in patients with PNH, adherence to anticomplement therapies is essential to maintain stable hematologic response while avoiding adverse events of breakthrough hemolysis and thrombosis. Real-world adherence to pegcetacoplan in patients with PNH was evaluated and compared with reported real-world adherence to long-term oral therapies for chronic conditions. Methods: A descriptive review of recent literature was conducted to summarize real-word oral medication adherence rates in chronic conditions. The Medical Subject Headings “compliance, medication” and “administration, oral” were applied in PubMed, and yielded reports on oral antidiabetic medications (OADs) in type 2 diabetes, oral anticoagulants (OACs) in atrial fibrillation (AF), and oral oncolytics in hematologic cancers; observational, real-world studies reporting medication adherence rates were reviewed and summarized. Adherence to pegcetacoplan therapy among patients with PNH in the US postmarketing setting was calculated as the percentage of patients who take pegcetacoplan as prescribed (adherence definition) based on the number of days patients had pegcetacoplan vials in their possession (dispensed) divided by the total number of days in a dispensing period (proportion of days covered) using central pharmacy prescription refill data. Results: In general, patients who take ≥80% of prescribed doses are considered adherent; using this definition, adherence rates among patients receiving long-term therapies for chronic conditions are typically 50% to 60% but vary greatly [Kleinsinger F. Perm J. 2018;22:18-033]. For example, reported OAD adherence rates in type 2 diabetes vary across countries (42% in Switzerland [Huber CA et al. Medicine (Baltimore). 2016;95:e3994] to 67% in Canada [Simard P et al. Acta Diabetol. 2015;52:547]) and by medication types (36.7% with thiazolidinediones to 47.3% with dipeptidyl peptidase 4-inhibitors [Farr AM et al. Adv Ther. 2014;31:1287]). OAC adherence rates in AF range widely (~40% to ~90%), differing across countries, patient populations (incident AF vs. post cardiovascular event), OAC types (warfarin, direct OACs), and follow-up period lengths. OAC adherence is also influenced by patient demographic and clinical characteristics and regional determinants in US Medicare beneficiaries [Hernandez I et al. J Am Heart Assoc. 2019;8:e011427]. Interestingly, an inverse relationship between oral medication adherence and dosing frequency is observed in chronic diseases in general (progressively decreasing adherence rates from once-daily to twice, 3-times, and 4-times daily dosing regimens [Coleman CI et al. J Manag Care Pharm. 2012;18:527]), and with OACs in AF [Vrijens B, Heidbuchel H. Europace. 2015;17:514]. As with other chronic conditions, nonadherence to oral oncolytics in hematologic cancers is more prevalent than suspected (32.7%) and associated with poorer clinical response [Noens L et al. Blood. 2009;113:5401], which can further increase the economic burden on patients [Dashputre AA et al. J Manag Care Spec Pharm. 2020;26:186]. Pegcetacoplan adherence for PNH in the US postmarketing setting from launch (2021) to date (2024) was estimated at 97%, well above the 80% threshold defining medication adherence in the literature. Conclusions: Real-world patients with PNH who self-administer pegcetacoplan subcutaneously have adherence rates exceeding the reported real-world adherence rates for oral medications in chronic conditions, especially those with high dosing frequencies. Retaining a stable hematologic response and preventing potentially life-threatening complications in PNH relies on continuous patient adherence to lifelong anticomplement therapies.
Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)
Gupta, S. C. , Ng, Lay She , Khurana, Arushi , Cook, Joselle , Kourelis, Taxiarchis , Abdallah, Nadine , Hampel, Paul J. , Warsame, Rahma , Hayman, Suzanne R. , Leung, Nelson , Kapoor, Prashant , Kumar, Shaji , Johnston, Patrick B. , Ansell, Stephen M. , Lin, Yi , Gupta, Supriya, Muñoz, Javier , Bennani, N. Nora , Paludo, Jonas , Cook, Joselle , Villasboas, José C. , Wang, Yucai , Gertz, Morie A. , Iqbal, Madiha , Dingli, David , Durani, Urshila

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 7589-7589

10.1182/blood-2024-210586 Get It

Background: Despite effective front-line therapies, DLBCL & MM have high relapse rates. Novel therapies like CAR-T & bispecific antibodies (BsAb) offer deep & durable remission compared to salvage therapies, but have a unique toxicity profile (TP) that requires monitoring. With no head-to-head trials, the rationale for therapy selection may vary. This study explores provider choices, sequencing preferences, & access barriers. Methods: Two anonymous surveys (MM and DLBCL) of US-based Hematologists were conducted from 2/2024 to 6/2024, on practice settings, CAR-T & BsAb availability, treatment preferences & barriers. Responses were analyzed to assess preferences across clinical scenarios. Results: Surveys were completed by 37 MM & 45 DLBCL providers. Most were at centers offering both CAR-T & BsAb. Most gave CAR-T inpatient, & BsAb outpatient. CAR-T was given by 73% MM providers & 66% DLBCL (92% used Cilta-cel, 96% used Ide-cel; 100% used Axi-cel, 90% used Liso-cel & 73% Tisa-cel). In MM, 78% used Teclistamab, 60% Talquetamab & 24% Elranatamab. In DLBCL, 62% used Epcoritamab & 40% Glofitamab. Providers preferred CAR-T over BsAb in MM after 4+ prior lines of therapy (LOT) (89%), & in DLBCL after 2+ prior LOT (93%). CAR-T was favored more among academic providers & those at CAR-T centers. Practice volume did not impact selection. Among providers at centers with BsAb-only, CAR-T was preferred by 60% (MM) and 50% (DLBCL). Providers at centers without both favored CAR-T (MM: 75%, DLBCL: 86%). CAR-T was chosen for better outcomes, short treatment, center choice, & prior experience. Other factors that influenced decisions were lower incidence of cytopenia/infection & “BsAb effective post-CAR-T, less so vice versa” (MM), & “curative potential of CAR-T” (DLBCL). Logistical barriers & institutional constraints influenced BsAb selection: CAR-T unavailability, access to specialized centers, referral complexity, insurance delay, manufacturing delay & hospitalization needs. In MM, 78% providers preferred Cilta-cel over Ide-cel, especially academic providers & those with CAR-T experience. CAR-T volume did not impact selection. Cilta-cel was preferred due to perceived better response rate (RR), more experience, “progression-free survival (PFS) benefit”, center choice, & logistical issues with Ide-cel. Ide-cel was selected due to center choice, favorable TP & insurance preference. Teclistamab was preferred by 78% due to more experience, better RR, TP & center choice, Elranatamab by 11% (better TP, RR, & “PFS”), & Talquetamab by 11% due to having a non-BCMA target. Academic providers preferred Teclistamab (89% vs 50%), & nonacademic providers preferred Talquetamab (38% vs 4%) and Elranatamab (13% vs 8%). In DLBCL after 2+ LOT, 69% favored Axi-cel due to prior experience, RR, center choice, & logistical issues with other products. Liso-cel & Tisa-cel were chosen by 27% & 2%, respectively, due to favorable TP. Axi-cel was also preferred 2nd line by 73% for similar reasons, while 24% favored Liso-cel for its favorable TP. Epcoritamab was preferred by 56% (subcutaneous injection, more experience & center choice) & Glofitamab by 42% (shorter treatment duration, easy administration, more experience, & center choice). Practice setting & volume did not impact selection between products in DLBCL. InBCMA-naïve MM pts, majority (97%) chose an anti-BCMA agent over GPRC5D due to better RR, TP, prior experience, & center choice. InBCMA-exposed pts, most (92%) favored an anti-GPRC5D agent. In contrast in DLBCL, 80% chose CD19 CAR-T after prior CD19-directed therapy, & 18% chose CD20 BsAb. Therefore, antigen escape was less of a concern in DLBCL vs MM. For relapse after 2nd line CAR-T in DLBCL, 78% preferred BsAb over other salvage options due to better RR, TP, & more experience. Providers prioritized RR, survival, & TP in decision making. Treatment logistics, duration, frequency, & cost were less crucial. MM providers also prioritized quality of life, which was less so in DLBCL. There were no differences in priority based on practice setting & experience with CAR-T. Conclusion: The study highlights factors influencing therapy choices in MM & DLBCL. Despite CAR-T's potential for better outcomes, significant access barriers exist. Efforts to streamline referral pathways, logistics, & expanding availability are crucial to improve outcomes. Understanding these preferences & barriers can guide future management strategies.
Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites
Kumar, Shaji , Dachs, Laura Rosiñol, Monge, Jorge, Leleu, Xavier , Rubia, Javier de la , Mateos, María-Victoria, Gozzetti, Alessandro , Bladé, Joan , Nagaraj, Madhu , Hassan, Rafla , Green, Jeannette, Kroog, Glenn S. , Lorenc, Karen Rodriguez , Ma, Qiufei , Durie, Brian G.M. , Gozzetti, Alessandro , Jagannath, Sundar , Weisel, Katja C , Dimopoulos, Meletios Α. , Siegel, David S. , Monge, Jorge , Du, Juan , Lee, Jae Hoon , Mateos, María‐Victoria , Dytfeld, Dominik , Ocio, Enrique M. , Ozaki, Shuji , Hampp, Christian

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 7039-7039

10.1182/blood-2024-210376 Get It

Introduction Multiple myeloma (MM) is considered incurable. Despite improved outcomes with novel agents, including BCMA-targeted chimeric antigen receptor (CAR) T-cell therapies, antibody-drug conjugates (ADCs), and bispecific antibodies, patients with relapsed/refractory MM (RRMM) often have poor prognoses. LINKER-MM1 (NCT03761108) is a global, single-arm, Phase 1/2 study of linvoseltamab, a BCMA×CD3 bispecific antibody, in patients with RRMM who were either triple-class exposed (TCE; previously treated with a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody) during ≥3 prior lines of therapy (LOTs), or triple-class refractory to these therapies. Here, we present comparisons of clinical outcomes from LINKER-MM1 with those of a current, international, real-world (RW) external control arm (ECA; NCT05673967). Methods The ECA was derived from 16 academic sites of the International Myeloma Foundation International Myeloma Working Group (IMWG) (N=203; 309 eligible LOTs) and compared with linvoseltamab (N=105; Phase 2 200 mg cohort). Patients in the ECA initiated ≥1 anti-MM therapy after meeting key LINKER-MM1 eligibility criteria. Weighted random sampling and inverse probability of treatment weighting were used to select 1 LOT per patient and balance the ECA and trial populations on prespecified prognostic factors (Kumar S, et al. IMS 2023). The primary endpoint was objective response rate (ORR; IMWG criteria) determined by an independent central review committee (ICRC) based on myeloma laboratories. An independent data review committee reviewed comparability of cohorts and endpoint assessments prior to conducting comparative analyses. Results Median follow-up was 14.3 months for the linvoseltamab cohort (data cutoff: Jan 6, 2024) and 13.4 months for the ECA. After weighting, 15 prognostic factors were balanced between cohorts. Patients in the ECA received 68 distinct regimens, most commonly CAR T-cell therapies (11.3%) and ADCs (10.3%). After balancing the cohorts, patients in the ECA evaluable for response had ICRC-assessed ORR of 46.3% (40.8% by treating physician assessment), among whom 24.0% had very good partial response or better (≥VGPR). When including patients who died without evaluable response, ECA ICRC-assessed ORR was 44.2%. Linvoseltamab induced significantly higher ICRC-assessed ORR (69.5% vs 46.3%, odds ratio [OR] 2.65 [95% confidence interval (CI) 1.66-3.69]) and rate of ≥VGPR (62.9% vs 24.0%, OR 5.37 [95% CI 3.61-8.49]) compared with ECA regimens. Conclusion Despite current use of novel therapies, there is no well-established RW standard of care (SOC) for patients with TCE RRMM treated at IMWG sites. To our knowledge, this is the first RW ECA study in MM with a high percentage of anti-BCMA therapies and response ascertainment for all patients by ICRC. Linvoseltamab induced significantly higher response rates, including rate of ≥VGPR, compared with current RW SOC therapies, highlighting its potential as a highly effective treatment in patients with TCE RRMM.
Prognostic impact of patient-reported symptoms in multiple myeloma
Abdallah, Nadine , Bohra, Arwa , Mammadzadeh, Aytaj , Buadi, Francis K. , Kapoor, Prashant , Gertz, Morie A. , Hayman, Suzanne R. , Elhaj, Mohammed, Dingli, David , Binder, Moritz , Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Thompson, Carrie A. , Kumar, Shaji , Buadi, Francis K , Dispenzieri, Angela , Gertz, Morie A , Cook, Joselle M , Binder, Moritz , Kourelis, Taxiarchis , Warsame, Rahma , Thompson, Carrie, Menser, Terri , Kumar, Shaji K , Dingli, David , Dispenzieri, Angela , Cook, Joselle , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | December 5, 2024 | Volume: 9 | Issue: 4 | Pages: 884-892

10.1182/bloodadvances.2024014232 | PMID 39637309 Get It

Abstract Patient-reported outcomes (PROs) are associated with treatment outcomes in multiple myeloma (MM) in the clinical trial setting. However, most PRO tools are time consuming, which hinders use in routine practice. Our institution incorporated a “Hematology Patient-Reported Symptom Screen” (HPRSS), a 3-item questionnaire for fatigue, pain, and quality of life (QOL). The main objective of this study was to evaluate the impact of these symptoms on progression-free survival (PFS) and overall survival (OS) in a real-world cohort of patients with newly diagnosed MM. This retrospective study included patients with MM diagnosed between April 2011 and December 2017, seen at Mayo Clinic (Rochester, MN), who completed the HPRSS. Patients rated their symptoms on a scale from 0 to 10. Clinically relevant symptoms were defined as scores ≥5 for pain and fatigue, and ≤5 for QOL. At diagnosis, 735 patients had scores for all domains. The median follow-up was 8.1 years. Age was associated with increased odds of fatigue and decreased QOL. Female sex and comorbidities were associated with fatigue and pain. Higher disease stage, anemia, lytic lesions, and increased plasma cell burden were associated with fatigue, pain, and decreased QOL. Clinically relevant fatigue, pain, and decreased QOL were associated with decreased PFS and OS. On multivariate analysis including age, International Staging System III, high-risk cytogenetics, and postinduction transplantation, fatigue and decreased QOL were independently associated with decreased OS. A composite HPRSS score stratified patients into 3 groups with distinct OS. Patient-reported symptoms are prognostic in patients with newly diagnosed MM. The prognostic values of fatigue and decreased QOL are independent of age, disease stage, and transplant status.
A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer
Wu, Bogang , Thant, Win , Bitman, Elena , Liu, Ting , Liu, Jie , Patel, Bidish K., Nawrocki, Cole, Xu, Katherine , Nieman, Linda T., Ting, David T., Macedo, Bruna de Gois, Cheng, Yang, Jiang, Kevin, Sun, Fengfei, Thimmiah, Nayana, Sun, Sheng , Bossuyt, Veerle I., Isakoff, Steven J. , Bardia, Aditya, Wu, Bogang , Liu, T., Liu, Jie, Paschalis, Eleftherios I. , Patel, Bidish K. , Nawrocki, Cole , Xu, K., Nieman, Linda T. , Ting, David T. , Macedo, Bruna de Gois , Cheng, Yang, Jiang, Kevin , Sun, Fengfei, Thimmiah, Nayana , Sun, S., Abelman, Rachel O. , Bossuyt, Veerle , Spring, L., Bardia, Aditya , Ellisen, Leif W.

Mayo Clinic

No container title available | December 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2024.12.02.626446 | PMID 39677819 Get It

ABSTRACT Background Immune exclusion inhibits anti-tumor immunity and response to immunotherapy, but its mechanisms remain poorly defined. In triple-negative breast cancer (TNBC), an aggressive and generally immune-rich subtype, an immune-cold microenvironment predicts poor prognosis due to a limited response to chemotherapy and immune checkpoint inhibitors. This study aimed to identify mechanisms regulating immune infiltration in TNBC. Methods We performed spatial transcriptomic analysis comparing immune-enriched versus immune-cold treatment-naïve TNBCs. Functional analyses, including loss-of-function and reconstitution experiments, were conducted to investigate the role of Trophoblast Cell-Surface Antigen 2 (TROP2), a key target of anti-cancer Antibody Drug Conjugates (ADCs), in promoting TNBC progression. A humanized TROP2 syngeneic TNBC model was used to assess the effects of TROP2-targeting in combination with anti-PD1 therapy. Additionally, data from patients treated with immune checkpoint blockade were used to test hypotheses from the preclinical findings. Results We reveal that TROP2 controls barrier-mediated immune exclusion in TNBC through Claudin 7 association and tight junction regulation. TROP2 expression is inversely correlated with T cell infiltration and predicts poor outcomes in TNBC. We demonstrate that TROP2 is sufficient to drive tumor progression in vivo in a CD8 T cell-dependent manner, while its loss deregulates expression and localization of multiple tight junction proteins, enabling T cell infiltration. We show that TROP2 targeting via hRS7, the antibody component of the ADC Sacituzumab govitecan (SG), enhances the anti-PD1 response and improves T cell accessibility and effector function. Correspondingly, TROP2 expression is highly associated with lack of response to anti-PD1 therapy in human breast cancer. Conclusions This study defines a new mechanism of barrier-mediated immune exclusion in cancer controlled by TROP2-dependent tight junctions. This mechanism drives tumor progression but can be targeted via TROP2-directed therapy to activate anti-tumor immunity and enhance immunotherapy response. What is already known on this topic Barrier-mediated immune exclusion is emerging as a mechanism of immune evasion in cancer such as triple-negative breast cancer (TNBC), but its molecular underpinnings remain poorly understood. TROP2 is a surface glycoprotein targeted by antibody-drug conjugates such as Sacituzumab govitecan, yet its functional role beyond drug delivery has been unclear. What this study adds This study identifies TROP2 as a key regulator of tight junction-mediated immune exclusion in TNBC, independent of its intracellular signaling function. TROP2 promotes an immune-cold tumor microenvironment by enforcing mechanical barriers that limit T cell infiltration. How this study might affect research, practice or policy These findings establish TROP2 as a functional driver of immune evasion and provide a mechanistic rationale for combining TROP2-targeting therapies with immune checkpoint inhibitors to overcome resistance in immune-excluded tumors.
Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis
Kumar, Shaji, Dachs, Laura Rosiñol, Leleu, Xavier , Rubia, Javier de la , Mateos, María‐Victoria , Martínez, Borja Puertas, Gozzetti, Alessandro , Bladé, Joan , Beksaç, Meral , Escalante, Fernando , Nagaraj, Madhu , Hassan, Rafla , Spin, Paul , Bonar, Nicolle , Siddiqui, Muhaimen, Hou, Kevin, Green, Jeannette, Breskin, Alexander , Harnett, James , Ge, Wenzhen , Jalbert, Jessica J. , Kroog, Glenn S. , Lorenc, Karen Rodriguez , Ma, Qiufei , Durie, Brian G.M. , Gozzetti, Alessandro , Kumar, Shaji , Jagannath, Sundar , Weisel, Katja C , Dimopoulos, Meletios Α. , Siegel, David S. , Monge, Jorge , Du, Juan , Lee, Jae Hoon , Puertas, Borja , Dytfeld, Dominik , Ocio, Enrique M. , Ozaki, Shuji , Shokoohi, Mostafa , Wang, Di, Humblet, Olivier , Sobel, Rachel E. , Hampp, Christian

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 7012-7012

10.1182/blood-2024-200679 Get It

Introduction Linvoseltamab is an investigational, BCMA×CD3 bispecific antibody designed for the treatment of RRMM. High objective response rates (ORR) to linvoseltamab 200 mg in the LINKER-MM1 trial (NCT03761108) were demonstrated across high-risk subgroups, including patients aged ≥75 years, patients with high-risk cytogenetics, and patients with penta-class refractory status. The aim of this study was to compare ORR, overall and in key subgroups, between patients in Phase 2 of the LINKER-MM1 trial and patients in an international RW SOC external control arm (ECA). Methods The ECA was derived from a chart review of 16 academic sites across 10 countries that are part of the International Myeloma Foundation (IMF)-International Myeloma Working Group (IMWG) and 2 US electronic health record databases (COTA and Guardian Research Network [GRN]). Included patients initiated ≥1 anti-MM treatment after meeting key eligibility criteria of LINKER-MM1. Weighted random sampling and inverse probability of treatment weighting (IPTW) were used to select 1 line of therapy (LOT) per patient and balance the overall ECA and trial populations on prespecified prognostic factors (Kumar S, et al. IMS 2023). For ORR assessment, LINKER-MM1 and IMF-IMWG used independent central review committees per IMWG criteria, COTA used algorithmic assessment based on IMWG criteria, and GRN used physician-assessed responses. Prior to conducting comparative analyses, an independent committee of epidemiology and oncology experts reviewed the comparability of the cohorts and endpoint assessments, and approved study continuation. ORR among patients in LINKER-MM1 and patients in the ECA was compared overall and across prespecified subgroups (≥10 patients per subgroup), including age, race, cytogenetic risk score, international Staging System (ISS), presence of extramedullary plasmacytoma (EMP), refractory class, bone marrow plasma cell (BMPC) proportion, and number of prior LOTs. Results Median duration of follow-up was 14.3 months (data cut-off: January 6, 2024) for patients receiving linvoseltamab (n=105) and 13.6 months for the ECA (n=307; n=194, n=72, and n=41 from IMF-IMWG, COTA, and GRN, respectively). Following IPTW, 13 prognostic factors with <30% missingness were balanced between cohorts, with an effective sample size in the ECA of 197. After adjustment, ORR was significantly higher in patients who received linvoseltamab compared with patients in the ECA (69.5% vs 45.7%, odds ratio [OR] 2.5 [95% confidence interval (CI) 1.6-4.1]) and in key subgroups with age 65-74 years (76.9% vs 48.3%, OR 3.6 [1.6-8.6]), age ≥75 years (72.4% vs 48.5%, OR 2.8 [1.1-7.4]), Black or African American race (82.4% vs 25.0%, OR 14.0 [3.0-85.4]), White race (68.9% vs 49.7%, OR 2.2 [1.3-4.0]), standard cytogenetic risk (72.3% vs 51.3%, OR 2.5 [1.3-4.8]), ISS stage III (58.8% vs 19.7%, OR 5.8 [1.5-25.2]), absence of EMP (71.6% vs 49.3%, OR 2.6 [1.5-4.6]), triple-class refractory status (68.2% vs 45.7%, OR 2.6 [1.5-4.4]), quadruple-class refractory status (66.7% vs 45.9%, OR 2.4 [1.3-4.3]), 4-5 prior LOTs (65.1% vs 40.4%, OR 2.8 [1.3-6.0]), and >5 prior LOTs (75.7% vs 36.1%, OR 5.5 [2.4-13.6]). Numerically higher (not statistically significant) or similar ORR was observed for patients receiving linvoseltamab compared with patients in the ECA with age <65 years (59.5% vs 46.8%, OR 1.7 [0.79-3.6]), high-risk cytogenetics (65.0% vs 63.1%, OR 1.1 [0.41-2.9]), ISS stage I (73.3% vs 64.6%, OR 1.5 [0.62-3.7]), ISS stage II (67.6% vs 53.5%, OR 1.8 [0.72-4.7]), presence of EMP (58.8% vs 56.9%, OR 1.1 [0.32-3.8]), penta-class refractory status (64.3% vs 48.5%, OR 1.9 [0.78-4.8]), BMPC <50% (77.0% vs 67.2%, OR 1.6 [0.61-4.3]), BMPC ≥50% (41.7% vs 36.0%, OR 1.3 [0.36-4.7]), and ≤3 prior LOTs (68.0% vs 66.4%, OR 1.1 [0.43-2.9]). Separate findings will be presented for IMF-IMWG and COTA/GRN data at the congress. Conclusions Linvoseltamab induced better ORR vs RW SOC treatments overall, and better or similar ORR in the key subgroups assessed, highlighting its therapeutic value across a range of patients with RRMM with heterogeneous risk profiles and levels of disease burden.